JavaScript seems to be disabled in your browser. You must have JavaScript enabled in your browser to utilize the functionality of this website.
Hepatocellular carcinoma Origin: Established from the tumor tissue of a 15-year-old Argentine boy Species:Homo sapiens Tissue:Liver Morphology:Epithelial Properties:Adherent Cytogenic data:human hyperdiploid karyotype Patient:Male, 15 yrs of age Medium:AddexBio-formulated RPMI-1640 Medium(C0004-01) + 10% FBS Subculture:1:2 to 1:4 using 0.25% trypsin or trypsin/EDTA, 5% CO2; 37C Freezing Medium:Complete culture medium supplemented with 5% (v/v) DMSO Biosafety Level: I Sterility: Bacteria: Negative Yeast: Negative Mycoplasma: Negative Pathogens: HIV: Negative Hepatitis B: Negative Hepatitis C: Negative Protein Expression: Express insulin, insulin-like growth factor II (IGF II), 3-hydroxy-3-methylglutaryl-CoA reductase and hepatic triglyceride lipase activities; decreased expression of apoA-I mRNA and increased expression of catalase mRNA in response to gramoxone DNA Profile (STR): Amelogenin: X, Y CSF1PO: 10, 11 D13S317: 9, 13 D16S539: 12, 13 D5S818: 11, 13 D7S820: 10 THO1: 9 TPOX: 8, 9 vWA: 17 D3S1358: 15, 16 D21S11: 29, 31 D18S51: 13, 14 Penta E: 15, 20 Penta D: 9, 13 D8S1179: 15, 16/17 FGA: 22, 25 Mutations in HepG2 Cells Related cells by Organ: Hep3B cells HepG2 cells
Established from the tumor tissue of a 15-year-old Argentine boy Species:Homo sapiens Tissue:Liver Morphology:Epithelial Properties:Adherent Cytogenic data:human hyperdiploid karyotype Patient:Male, 15 yrs of age Medium:AddexBio-formulated RPMI-1640 Medium(C0004-01) + 10% FBS Subculture:1:2 to 1:4 using 0.25% trypsin or trypsin/EDTA, 5% CO2; 37C Freezing Medium:Complete culture medium supplemented with 5% (v/v) DMSO Biosafety Level: I Sterility: Bacteria: Negative Yeast: Negative Mycoplasma: Negative Pathogens: HIV: Negative Hepatitis B: Negative Hepatitis C: Negative Protein Expression: Express insulin, insulin-like growth factor II (IGF II), 3-hydroxy-3-methylglutaryl-CoA reductase and hepatic triglyceride lipase activities; decreased expression of apoA-I mRNA and increased expression of catalase mRNA in response to gramoxone DNA Profile (STR): Amelogenin: X, Y CSF1PO: 10, 11 D13S317: 9, 13 D16S539: 12, 13 D5S818: 11, 13 D7S820: 10 THO1: 9 TPOX: 8, 9 vWA: 17 D3S1358: 15, 16 D21S11: 29, 31 D18S51: 13, 14 Penta E: 15, 20 Penta D: 9, 13 D8S1179: 15, 16/17 FGA: 22, 25 Mutations in HepG2 Cells Related cells by Organ: Hep3B cells HepG2 cells
Homo sapiens Tissue:Liver Morphology:Epithelial Properties:Adherent Cytogenic data:human hyperdiploid karyotype Patient:Male, 15 yrs of age Medium:AddexBio-formulated RPMI-1640 Medium(C0004-01) + 10% FBS Subculture:1:2 to 1:4 using 0.25% trypsin or trypsin/EDTA, 5% CO2; 37C Freezing Medium:Complete culture medium supplemented with 5% (v/v) DMSO Biosafety Level: I Sterility: Bacteria: Negative Yeast: Negative Mycoplasma: Negative Pathogens: HIV: Negative Hepatitis B: Negative Hepatitis C: Negative Protein Expression: Express insulin, insulin-like growth factor II (IGF II), 3-hydroxy-3-methylglutaryl-CoA reductase and hepatic triglyceride lipase activities; decreased expression of apoA-I mRNA and increased expression of catalase mRNA in response to gramoxone DNA Profile (STR): Amelogenin: X, Y CSF1PO: 10, 11 D13S317: 9, 13 D16S539: 12, 13 D5S818: 11, 13 D7S820: 10 THO1: 9 TPOX: 8, 9 vWA: 17 D3S1358: 15, 16 D21S11: 29, 31 D18S51: 13, 14 Penta E: 15, 20 Penta D: 9, 13 D8S1179: 15, 16/17 FGA: 22, 25 Mutations in HepG2 Cells Related cells by Organ: Hep3B cells HepG2 cells
Liver Morphology:Epithelial Properties:Adherent Cytogenic data:human hyperdiploid karyotype Patient:Male, 15 yrs of age Medium:AddexBio-formulated RPMI-1640 Medium(C0004-01) + 10% FBS Subculture:1:2 to 1:4 using 0.25% trypsin or trypsin/EDTA, 5% CO2; 37C Freezing Medium:Complete culture medium supplemented with 5% (v/v) DMSO Biosafety Level: I Sterility: Bacteria: Negative Yeast: Negative Mycoplasma: Negative Pathogens: HIV: Negative Hepatitis B: Negative Hepatitis C: Negative Protein Expression: Express insulin, insulin-like growth factor II (IGF II), 3-hydroxy-3-methylglutaryl-CoA reductase and hepatic triglyceride lipase activities; decreased expression of apoA-I mRNA and increased expression of catalase mRNA in response to gramoxone DNA Profile (STR): Amelogenin: X, Y CSF1PO: 10, 11 D13S317: 9, 13 D16S539: 12, 13 D5S818: 11, 13 D7S820: 10 THO1: 9 TPOX: 8, 9 vWA: 17 D3S1358: 15, 16 D21S11: 29, 31 D18S51: 13, 14 Penta E: 15, 20 Penta D: 9, 13 D8S1179: 15, 16/17 FGA: 22, 25 Mutations in HepG2 Cells Related cells by Organ: Hep3B cells HepG2 cells
Epithelial Properties:Adherent Cytogenic data:human hyperdiploid karyotype Patient:Male, 15 yrs of age Medium:AddexBio-formulated RPMI-1640 Medium(C0004-01) + 10% FBS Subculture:1:2 to 1:4 using 0.25% trypsin or trypsin/EDTA, 5% CO2; 37C Freezing Medium:Complete culture medium supplemented with 5% (v/v) DMSO Biosafety Level: I Sterility: Bacteria: Negative Yeast: Negative Mycoplasma: Negative Pathogens: HIV: Negative Hepatitis B: Negative Hepatitis C: Negative Protein Expression: Express insulin, insulin-like growth factor II (IGF II), 3-hydroxy-3-methylglutaryl-CoA reductase and hepatic triglyceride lipase activities; decreased expression of apoA-I mRNA and increased expression of catalase mRNA in response to gramoxone DNA Profile (STR): Amelogenin: X, Y CSF1PO: 10, 11 D13S317: 9, 13 D16S539: 12, 13 D5S818: 11, 13 D7S820: 10 THO1: 9 TPOX: 8, 9 vWA: 17 D3S1358: 15, 16 D21S11: 29, 31 D18S51: 13, 14 Penta E: 15, 20 Penta D: 9, 13 D8S1179: 15, 16/17 FGA: 22, 25 Mutations in HepG2 Cells Related cells by Organ: Hep3B cells HepG2 cells
Adherent Cytogenic data:human hyperdiploid karyotype Patient:Male, 15 yrs of age Medium:AddexBio-formulated RPMI-1640 Medium(C0004-01) + 10% FBS Subculture:1:2 to 1:4 using 0.25% trypsin or trypsin/EDTA, 5% CO2; 37C Freezing Medium:Complete culture medium supplemented with 5% (v/v) DMSO Biosafety Level: I Sterility: Bacteria: Negative Yeast: Negative Mycoplasma: Negative Pathogens: HIV: Negative Hepatitis B: Negative Hepatitis C: Negative Protein Expression: Express insulin, insulin-like growth factor II (IGF II), 3-hydroxy-3-methylglutaryl-CoA reductase and hepatic triglyceride lipase activities; decreased expression of apoA-I mRNA and increased expression of catalase mRNA in response to gramoxone DNA Profile (STR): Amelogenin: X, Y CSF1PO: 10, 11 D13S317: 9, 13 D16S539: 12, 13 D5S818: 11, 13 D7S820: 10 THO1: 9 TPOX: 8, 9 vWA: 17 D3S1358: 15, 16 D21S11: 29, 31 D18S51: 13, 14 Penta E: 15, 20 Penta D: 9, 13 D8S1179: 15, 16/17 FGA: 22, 25 Mutations in HepG2 Cells Related cells by Organ: Hep3B cells HepG2 cells
human hyperdiploid karyotype Patient:Male, 15 yrs of age Medium:AddexBio-formulated RPMI-1640 Medium(C0004-01) + 10% FBS Subculture:1:2 to 1:4 using 0.25% trypsin or trypsin/EDTA, 5% CO2; 37C Freezing Medium:Complete culture medium supplemented with 5% (v/v) DMSO Biosafety Level: I Sterility: Bacteria: Negative Yeast: Negative Mycoplasma: Negative Pathogens: HIV: Negative Hepatitis B: Negative Hepatitis C: Negative Protein Expression: Express insulin, insulin-like growth factor II (IGF II), 3-hydroxy-3-methylglutaryl-CoA reductase and hepatic triglyceride lipase activities; decreased expression of apoA-I mRNA and increased expression of catalase mRNA in response to gramoxone DNA Profile (STR): Amelogenin: X, Y CSF1PO: 10, 11 D13S317: 9, 13 D16S539: 12, 13 D5S818: 11, 13 D7S820: 10 THO1: 9 TPOX: 8, 9 vWA: 17 D3S1358: 15, 16 D21S11: 29, 31 D18S51: 13, 14 Penta E: 15, 20 Penta D: 9, 13 D8S1179: 15, 16/17 FGA: 22, 25 Mutations in HepG2 Cells Related cells by Organ: Hep3B cells HepG2 cells
Male, 15 yrs of age Medium:AddexBio-formulated RPMI-1640 Medium(C0004-01) + 10% FBS Subculture:1:2 to 1:4 using 0.25% trypsin or trypsin/EDTA, 5% CO2; 37C Freezing Medium:Complete culture medium supplemented with 5% (v/v) DMSO Biosafety Level: I Sterility: Bacteria: Negative Yeast: Negative Mycoplasma: Negative Pathogens: HIV: Negative Hepatitis B: Negative Hepatitis C: Negative Protein Expression: Express insulin, insulin-like growth factor II (IGF II), 3-hydroxy-3-methylglutaryl-CoA reductase and hepatic triglyceride lipase activities; decreased expression of apoA-I mRNA and increased expression of catalase mRNA in response to gramoxone DNA Profile (STR): Amelogenin: X, Y CSF1PO: 10, 11 D13S317: 9, 13 D16S539: 12, 13 D5S818: 11, 13 D7S820: 10 THO1: 9 TPOX: 8, 9 vWA: 17 D3S1358: 15, 16 D21S11: 29, 31 D18S51: 13, 14 Penta E: 15, 20 Penta D: 9, 13 D8S1179: 15, 16/17 FGA: 22, 25 Mutations in HepG2 Cells Related cells by Organ: Hep3B cells HepG2 cells
AddexBio-formulated RPMI-1640 Medium(C0004-01) + 10% FBS Subculture:1:2 to 1:4 using 0.25% trypsin or trypsin/EDTA, 5% CO2; 37C Freezing Medium:Complete culture medium supplemented with 5% (v/v) DMSO Biosafety Level: I Sterility: Bacteria: Negative Yeast: Negative Mycoplasma: Negative Pathogens: HIV: Negative Hepatitis B: Negative Hepatitis C: Negative Protein Expression: Express insulin, insulin-like growth factor II (IGF II), 3-hydroxy-3-methylglutaryl-CoA reductase and hepatic triglyceride lipase activities; decreased expression of apoA-I mRNA and increased expression of catalase mRNA in response to gramoxone DNA Profile (STR): Amelogenin: X, Y CSF1PO: 10, 11 D13S317: 9, 13 D16S539: 12, 13 D5S818: 11, 13 D7S820: 10 THO1: 9 TPOX: 8, 9 vWA: 17 D3S1358: 15, 16 D21S11: 29, 31 D18S51: 13, 14 Penta E: 15, 20 Penta D: 9, 13 D8S1179: 15, 16/17 FGA: 22, 25 Mutations in HepG2 Cells Related cells by Organ: Hep3B cells HepG2 cells
1:2 to 1:4 using 0.25% trypsin or trypsin/EDTA, 5% CO2; 37C Freezing Medium:Complete culture medium supplemented with 5% (v/v) DMSO Biosafety Level: I Sterility: Bacteria: Negative Yeast: Negative Mycoplasma: Negative Pathogens: HIV: Negative Hepatitis B: Negative Hepatitis C: Negative Protein Expression: Express insulin, insulin-like growth factor II (IGF II), 3-hydroxy-3-methylglutaryl-CoA reductase and hepatic triglyceride lipase activities; decreased expression of apoA-I mRNA and increased expression of catalase mRNA in response to gramoxone DNA Profile (STR): Amelogenin: X, Y CSF1PO: 10, 11 D13S317: 9, 13 D16S539: 12, 13 D5S818: 11, 13 D7S820: 10 THO1: 9 TPOX: 8, 9 vWA: 17 D3S1358: 15, 16 D21S11: 29, 31 D18S51: 13, 14 Penta E: 15, 20 Penta D: 9, 13 D8S1179: 15, 16/17 FGA: 22, 25 Mutations in HepG2 Cells Related cells by Organ: Hep3B cells HepG2 cells
Complete culture medium supplemented with 5% (v/v) DMSO Biosafety Level: I Sterility: Bacteria: Negative Yeast: Negative Mycoplasma: Negative Pathogens: HIV: Negative Hepatitis B: Negative Hepatitis C: Negative Protein Expression: Express insulin, insulin-like growth factor II (IGF II), 3-hydroxy-3-methylglutaryl-CoA reductase and hepatic triglyceride lipase activities; decreased expression of apoA-I mRNA and increased expression of catalase mRNA in response to gramoxone DNA Profile (STR): Amelogenin: X, Y CSF1PO: 10, 11 D13S317: 9, 13 D16S539: 12, 13 D5S818: 11, 13 D7S820: 10 THO1: 9 TPOX: 8, 9 vWA: 17 D3S1358: 15, 16 D21S11: 29, 31 D18S51: 13, 14 Penta E: 15, 20 Penta D: 9, 13 D8S1179: 15, 16/17 FGA: 22, 25 Mutations in HepG2 Cells Related cells by Organ: Hep3B cells HepG2 cells
Bacteria: Negative Yeast: Negative Mycoplasma: Negative Pathogens: HIV: Negative Hepatitis B: Negative Hepatitis C: Negative Protein Expression: Express insulin, insulin-like growth factor II (IGF II), 3-hydroxy-3-methylglutaryl-CoA reductase and hepatic triglyceride lipase activities; decreased expression of apoA-I mRNA and increased expression of catalase mRNA in response to gramoxone DNA Profile (STR): Amelogenin: X, Y CSF1PO: 10, 11 D13S317: 9, 13 D16S539: 12, 13 D5S818: 11, 13 D7S820: 10 THO1: 9 TPOX: 8, 9 vWA: 17 D3S1358: 15, 16 D21S11: 29, 31 D18S51: 13, 14 Penta E: 15, 20 Penta D: 9, 13 D8S1179: 15, 16/17 FGA: 22, 25 Mutations in HepG2 Cells Related cells by Organ: Hep3B cells HepG2 cells
Yeast: Negative Mycoplasma: Negative Pathogens: HIV: Negative Hepatitis B: Negative Hepatitis C: Negative Protein Expression: Express insulin, insulin-like growth factor II (IGF II), 3-hydroxy-3-methylglutaryl-CoA reductase and hepatic triglyceride lipase activities; decreased expression of apoA-I mRNA and increased expression of catalase mRNA in response to gramoxone DNA Profile (STR): Amelogenin: X, Y CSF1PO: 10, 11 D13S317: 9, 13 D16S539: 12, 13 D5S818: 11, 13 D7S820: 10 THO1: 9 TPOX: 8, 9 vWA: 17 D3S1358: 15, 16 D21S11: 29, 31 D18S51: 13, 14 Penta E: 15, 20 Penta D: 9, 13 D8S1179: 15, 16/17 FGA: 22, 25 Mutations in HepG2 Cells Related cells by Organ: Hep3B cells HepG2 cells
Mycoplasma: Negative Pathogens: HIV: Negative Hepatitis B: Negative Hepatitis C: Negative Protein Expression: Express insulin, insulin-like growth factor II (IGF II), 3-hydroxy-3-methylglutaryl-CoA reductase and hepatic triglyceride lipase activities; decreased expression of apoA-I mRNA and increased expression of catalase mRNA in response to gramoxone DNA Profile (STR): Amelogenin: X, Y CSF1PO: 10, 11 D13S317: 9, 13 D16S539: 12, 13 D5S818: 11, 13 D7S820: 10 THO1: 9 TPOX: 8, 9 vWA: 17 D3S1358: 15, 16 D21S11: 29, 31 D18S51: 13, 14 Penta E: 15, 20 Penta D: 9, 13 D8S1179: 15, 16/17 FGA: 22, 25 Mutations in HepG2 Cells Related cells by Organ: Hep3B cells HepG2 cells
HIV: Negative Hepatitis B: Negative Hepatitis C: Negative Protein Expression: Express insulin, insulin-like growth factor II (IGF II), 3-hydroxy-3-methylglutaryl-CoA reductase and hepatic triglyceride lipase activities; decreased expression of apoA-I mRNA and increased expression of catalase mRNA in response to gramoxone DNA Profile (STR): Amelogenin: X, Y CSF1PO: 10, 11 D13S317: 9, 13 D16S539: 12, 13 D5S818: 11, 13 D7S820: 10 THO1: 9 TPOX: 8, 9 vWA: 17 D3S1358: 15, 16 D21S11: 29, 31 D18S51: 13, 14 Penta E: 15, 20 Penta D: 9, 13 D8S1179: 15, 16/17 FGA: 22, 25 Mutations in HepG2 Cells Related cells by Organ: Hep3B cells HepG2 cells
Hepatitis B: Negative Hepatitis C: Negative Protein Expression: Express insulin, insulin-like growth factor II (IGF II), 3-hydroxy-3-methylglutaryl-CoA reductase and hepatic triglyceride lipase activities; decreased expression of apoA-I mRNA and increased expression of catalase mRNA in response to gramoxone DNA Profile (STR): Amelogenin: X, Y CSF1PO: 10, 11 D13S317: 9, 13 D16S539: 12, 13 D5S818: 11, 13 D7S820: 10 THO1: 9 TPOX: 8, 9 vWA: 17 D3S1358: 15, 16 D21S11: 29, 31 D18S51: 13, 14 Penta E: 15, 20 Penta D: 9, 13 D8S1179: 15, 16/17 FGA: 22, 25 Mutations in HepG2 Cells Related cells by Organ: Hep3B cells HepG2 cells
Hepatitis C: Negative Protein Expression: Express insulin, insulin-like growth factor II (IGF II), 3-hydroxy-3-methylglutaryl-CoA reductase and hepatic triglyceride lipase activities; decreased expression of apoA-I mRNA and increased expression of catalase mRNA in response to gramoxone DNA Profile (STR): Amelogenin: X, Y CSF1PO: 10, 11 D13S317: 9, 13 D16S539: 12, 13 D5S818: 11, 13 D7S820: 10 THO1: 9 TPOX: 8, 9 vWA: 17 D3S1358: 15, 16 D21S11: 29, 31 D18S51: 13, 14 Penta E: 15, 20 Penta D: 9, 13 D8S1179: 15, 16/17 FGA: 22, 25 Mutations in HepG2 Cells Related cells by Organ: Hep3B cells HepG2 cells
Mutations in HepG2 Cells
Hep3B cells
HepG2 cells
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.
C0015002.pdf
Request safety datasheet
Delivery expected until 7/31/2025
Compare
Add to wishlist
Get an offer
Request delivery time
Ask a technical question
Submit a bulk request
sales@hoelzel.de
« Back
Subscribe, get 15% off every fifth order and have your items delivered on time!
Forgot Your Password?
Not yet registered? Create account here!